Chinese Hepatolgy ›› 2024, Vol. 29 ›› Issue (10): 1205-1208.

• Liver Cancer • Previous Articles     Next Articles

The application value of serum microRNA-142-3p and miR-493-5p expression levels in the early diagnosis and disease assessment of primary hepatocellular carcinoma

WANG Hui-zhe1, LU Shuang-dong2, WANG Qian3, LIU Long-yan4, WANG Ming-quan5   

  1. 1. Department of Gastroenterology,Baoding Second Central Hospital, Hebei, 072750, China;
    2. Department of Emergency, Baoding Second Central Hospital, Hebei 072750, China;
    3. Department of Radiology, Baoding Second Central Hospital, Hebei 072750, China;
    4. Department of Pentatology, Baoding Second Central Hospital, Hebei 072750, China;
    5. Department of Laboratory, Baoding Second Central Hospital, Hebei 072750, China
  • Received:2024-03-28 Online:2024-10-31 Published:2024-12-02

PDF (PC)

9

Abstract: Objective To explore the application value of serum microRNA(miR)-142-3p and miR-493-5p expression levels in the early diagnosis and disease assessment of primary hepatocellular carcinoma (PHC). Methods From June 2020 to August 2023, eighty-six PHC patients admitted to Baoding Second Central Hospital were collected as the PHC group, and 50 patients with autoimmune hepatitis were collected during the same period of time as the benign group. Additionally, 86 healthy individuals who underwent physical examination were collected as control group. Real-time quantitative fluorescence polymerase chain reaction (qRT-PCR) was used to measure the serum levels of miR-142-3p and miR-493-5p. Receiver operating characteristic (ROC) curve was applied to analyze the value of serum miR-142-3p and miR-493-5p in the early diagnosis and disease assessment of PHC. Results The expression levels of miR-142-3p (0.79±0.21) and miR-493-5p (0.83±0.22) in the serum of the PHC group were significantly lower than those of the benign group [(0.89±0.11) and (0.92±0.10), respectively] and control group [(1.01±0.12) and (1.02±0.13), respectively] (P<0.05). The levels of serum miR-142-3p and miR-493-5p in PHC patients with tumor diameter ≥3cm, portal vein invasion, distant metastasis were obviously lower than those in patients with tumor diameter <3 cm, non-portal vein invasion, and non-distant metastasis (P<0.05); the expression levels of miR-142-3p [(0.76±0.06), (0.67±0.05)] and miR-493-5p [(0.81±0.09), (0.70±0.06)] in the serum of patients with stage III and IV PHC, respectively, were significantly lower than those in stages I-II [(0.89±0.09), (0.93±0.11)] (P<0.05). The AUC of the combination of serum miR-142-3p and miR-493-5p for early diagnosis of PHC was 0.910, which was obviously higher than that of the two alone (Z=3.184, 2.739, all P<0.05). The AUC of serum miR-142-3p combined with miR-493-5p for disease assessment was 0.940, which was obviously higher than those of the two assessment alone (Z=1.994, 2.470, all P<0.05). Conclusion MiR-142-3p and miR-493-5p are both low expressed in the serum of PHC patients, which can be used as serum biomarkers for the diagnosis and assessment of PHC. A combined detection of these two miRs can significantly improve the diagnostic and assessment efficiency of PHC.

Key words: Micro RNA-142-3p, Micro RNA-493-5p, Primary hepatocellular carcinoma, Diagnosis, Disease condition